Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells
- PMID: 29432847
- DOI: 10.1016/j.canlet.2018.02.013
Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells
Abstract
Ovarian cancer patients in the advanced stages of the disease show clinical ascites, which is associated with a poor prognosis. There is limited understanding of the effect of ascitic fluid on ovarian cancer cells and their response to anticancer drugs. We investigated the antitumour effects of EGFR/Her-2 (canertinib) and c-Met (PHA665752) inhibitors in a 3D cell model of three ovarian cancer lines. Single and combined inhibitor treatments affected cell growth of OVCAR-5 and SKOV-3 cell lines but not OV-90 cell line. Growth reduction was correlated with the down expression of PCNA, EGFR, HER-2, c-MET, ERK and AKT and their phosphorylation status in cells in growth factor supplemented media. However, these effects were not re-producible in OVCAR-5 and SKOV-3 cell lines when they were exposed to ascitic fluid obtained from three ovarian cancer patients. Serum albumin and protein components in the ascitic fluids may reduce the cellular uptake of the inhibitors.
Keywords: 3D cell culture; Ascites; EGFR; HER-2; Ovarian cancer; Targeted inhibitors; c-MET.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.Oncol Ther. 2016;4(2):257-274. doi: 10.1007/s40487-016-0031-1. Epub 2016 Sep 27. Oncol Ther. 2016. PMID: 28261654 Free PMC article.
-
Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.J Thorac Oncol. 2010 Sep;5(9):1317-24. doi: 10.1097/JTO.0b013e3181e2a409. J Thorac Oncol. 2010. PMID: 20736805
-
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30. Mol Cancer Ther. 2008. PMID: 18974395
-
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015. PLoS One. 2015. PMID: 26580964 Free PMC article.
-
EGFR/HER-targeted therapeutics in ovarian cancer.Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Future Med Chem. 2012. PMID: 22416774 Free PMC article. Review.
Cited by
-
The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade.J Exp Clin Cancer Res. 2019 Nov 6;38(1):455. doi: 10.1186/s13046-019-1468-5. J Exp Clin Cancer Res. 2019. PMID: 31694696 Free PMC article.
-
Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer.Biomedicines. 2022 Oct 25;10(11):2694. doi: 10.3390/biomedicines10112694. Biomedicines. 2022. PMID: 36359213 Free PMC article.
-
The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models.Cancers (Basel). 2022 Jan 13;14(2):395. doi: 10.3390/cancers14020395. Cancers (Basel). 2022. PMID: 35053555 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous